Navigation Links
ROX Medical secures financing and achieves key milestones in providing minimally-invasive approach for treating hypertension
Date:9/6/2012

SAN CLEMENTE, Calif., Sept. 6, 2012 /PRNewswire/ -- ROX Medical announced the closing of a financing round totaling $6M.  The financing will be used to initiate an international trial of the ROX FLOW procedure for the treatment of resistant hypertension (high blood pressure). Previously, ROX has successfully evaluated the FLOW procedure in pilot studies:  "The very encouraging results from our pilot hypertension trial was the basis for this investment, enabling us to pursue a more comprehensive, randomized study using the FLOW procedure," said CEO Rodney Brenneman.

According to the Centers for Disease Control, 68 million people in the US have high blood pressure and 1.2 billion people worldwide.  Of those, 50% of patients experience hypertension that remains uncontrolled (blood pressure above 140/90) and 15-20% have resistant form of hypertension. According to the American Heart Association, a 5 mmHg reduction in systolic blood pressure results in a 14% decrease in stroke, a 9% decrease in heart disease and a 7% decrease in overall mortality. 

ROX Medical's FLOW procedure is a short, minimally invasive, catheter-based procedure whereby Interventional Cardiologists, Radiologists or Endovascular Specialists place a stent-like connection between the artery and vein in the upper leg. The procedure is intended to reduce peripheral vascular resistance, thereby holding the promise of a meaningful long-term reduction in hypertension.  Uniquely, the FLOW procedure only involves the vascular structure, has an immediate effect; and is fully reversible.

To-date, ROX Medical has raised approximately $50M for its FLOW system, initially for studies and early commercialization of the FLOW procedure for COPD (pulmonary) treatment. The prior successful studies on COPD patients also demonstrated a significant lowering of blood pressure in hypertensive patients. "Hypertension physicians were encouraged by this response in our COPD patients, and pushed us to pursue this therapy separately for resistant hypertension patients as well.  We're excited to move forward with a randomized controlled trial," Brenneman said. Pilot results with the ROX FLOW procedure in resistant hypertensive patients have shown reductions in systolic and diastolic blood pressure on par with those for device therapies like renal denervation.

The ROX FLOW procedure for hypertension is not approved for use in the U.S.

Investors in the latest round of funding include continuing investors Domain Associates and Versant Ventures.


'/>"/>
SOURCE ROX Medical
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ventana Medical Systems, Inc. develops first-ever fully automated dual-stain technique for miRNA and protein detection in cancer
2. Medical Alarm Retires Last of Convertible Preferred Stock
3. Concord Medical Responds to Unusual Market Activity in its Stock
4. International Spine Products Manufacturer Featured in Upcoming US Business Executive Publication - www.gsmedicalusa.com
5. Medical Alarm Provides Investor Update -- Company Surpassing Previous Record Order Levels as Consumer Interest Accelerates
6. MyEvaluations.com Launches New Medical Education Management Solutions That Meet ACGME NAS Accreditation Requirements
7. Fall Alert Announces Its New Medical Alert Systems Website
8. Surefire Medicals Infusion System For Embolization Procedures Receives CE Mark Approval
9. Magnalight Releases Handheld Infrared Light for Medical Applications
10. GHX Selects MicroStrategy to Offer Healthcare Suppliers Enhanced Access to Distributed Medical-Surgical Market Data
11. Sacred Heart Medical Center Deploys Talysts Pharmacy Automation for Inventory Control and Improved Patient Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)...   Science Exchange , the leading marketplace ... the first five replication studies from the ... in eLife today. Despite intense scrutiny around reproducibility ... evaluation of reproducibility rates that may identify specific ... assessments of reproducibility, the results of this project ...
(Date:1/19/2017)... January 18, 2017 , , Marks E-QURE ... distribution agreement, following similar agreements in Israel ... Wound care is $2 5 billion ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of ... Médica Equipos Médicos S.A.S. (TeckMedica) in Colombia for the ...
(Date:1/19/2017)... , Jan. 18, 2017 The drug ... billion by 2021 from USD 1,179.20 billion in 2016, ... Increasing prevalence of chronic diseases, increasing demand for ... factors driving the growth of this market. Whereas, self-administration ... generic drugs offer significant growth opportunities for players operating ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... ... Cosmetic Town, an online plastic surgery community, begins 2017 with an update ... their readers to get the information they desire. The procedures are now listed according ... on those particular areas. , “We are excited to streamline our listings in a ...
(Date:1/19/2017)... Plains, NJ (PRWEB) , ... January 19, 2017 ... ... board certified dermatologist by the American Board of Dermatology and fellowship trained Mohs ... of the National Institutes of Health, Dr. Li completed his internship in internal ...
(Date:1/19/2017)... Angeles, California (PRWEB) , ... January 19, 2017 ... ... the hands of a doctor who administered fillers that resulted in severe facial ... unprecedented case was taken on by doctors at UCLA Medical Center, who removed ...
(Date:1/19/2017)... ... January 19, 2017 , ... Workrite Ergonomics ... , The Tranquility privacy panel system was designed to deliver the ideal ... help reduce noise and provide the visual privacy required to maintain concentration levels ...
(Date:1/19/2017)... Francisco, CA (PRWEB) , ... January 19, 2017 , ... ... financial planning assistance to commercial and residential clients in the California Bay Area, is ... positive heart health in the region. , Heart disease is the primary killer of ...
Breaking Medicine News(10 mins):